• Accelr8 Technology (Denver) reported study results that were presented at the ICAAC conference. The purpose of the study was to characterize a rapid test run on Accelr8's BACcel diagnostic system to detect a broad multiple antibiotic resistance mechanism known as "ESBL," which stands for "extended spectrum beta-lactamase." The study analyzed bacterial strains previously characterized for ESBL expression, and control strains that lacked the resistance enzymes. Species included Klebsiella pneumoniae and E. coli, which commonly infect ICU patients. These species are leading members of a large family of bacteria that account for approximately 25% to 35% of serious hospital infections.

• AngioDynamics (Queensbury, New York) said it will launch a new varicose vein therapy brand, VenaCure EVLT, at the American College of Phlebology annual congress. The new brand will encompass the best of AngioDynamics' VenaCure product line as well as EVLT, a product line which AngioDynamics recently acquired from Diomed. "As the name conveys, our new brand will be everything you liked about VenaCure and EVLT in one package," said Sean Morris, senior VP/GM of AngioDynamics' peripheral vascular division. "We have now combined the best of Diomed and AngioDynamics into a dream team offering for physicians and their patients. Patients get an effective, outpatient alternative to otherwise painful and invasive surgery."